Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to crack the code on insulin allergies

NCT ID NCT01407640

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study looks at 55 adults with diabetes who are either allergic to insulin or not, to better understand and diagnose insulin allergy. Researchers will test a step-by-step diagnostic approach and study the immune system's role. The goal is to make it easier to identify the exact cause of the allergy so that patients can continue receiving life-saving insulin safely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a reliable diagnostic test for insulin allergy, helping doctors identify the exact allergen and find safer treatment options.
What could go wrong
This is an observational study with no new treatment being tested. The findings may not lead to immediate changes in clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

55 people

The number who actually took part.

Started

Feb 2012

Finished

Jul 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria : * Patients aged 18 years old and more with a written informed consent * Experimental group : type 1 or type 2 diabetic patients with insulin allergy based on clinical criteria * Active Comparator group: type 1 or type 2 diabetic patients insulin treated without insulin allergy Exclusion criteria : * Not willing participate * Pregnancy * Age below 18 years * Severe Renal failure * Severe Anaphylactic shock only for the experimental group * No social security overture

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic disease diabetes mellitus Drug-Related Side Effects and Adverse Reactions hypersensitivity reaction disease Hypersensitivity, Immediate IgE responsiveness, atopic type 1 diabetes mellitus type 1 diabetes mellitus 1 type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergy Diabetes mellitus type 2 Diabetes mellitus, type 1 Hypersensitivity Immediate hypersensitivity

Contacts and locations

Locations

  • Cochin Hospital

    Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.